May 24, 2017
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.




Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)



Studies on the teratogenicity of pyrazole compounds in animals have yielded inconclusive results. Up to the present time, however, there have been no reported cases of human congenital malformation proved to be due to the use of the drug.

It is suggested that Anturane (sulfinpyrazone) be used with caution in pregnant women, weighing the potential risks against the possible benefits.


As with all pyrazole compounds, patients receiving Anturane (sulfinpyrazone) should be kept under close medical supervision and periodic blood counts are recommended. It may be administered with care to patients with a history of healed peptic ulcer.

Recent reports have indicated that Anturane (sulfinpyrazone) potentiates the action of certain sulfonamides, such as sulfadiazine and sulfisoxazole. In addition, other pyrazole compounds (phenylbutazone) have been observed to potentiate the hypoglycemic sulfonylurea agents, as well as insulin. In view of these observations, it is suggested that Anturane (sulfinpyrazone) be used with caution in conjunction with sulfa drugs, the sulfonylurea hypoglycemic agents and insulin.

Because Anturane (sulfinpyrazone) is a potent uricosuric agent, it may precipitate urolithiasis and renal colic, especially in the initial stages of therapy. For this reason, an adequate fluid intake and alkalinization of the urine are recommended. In cases with significant renal impairment, periodic assessment of renal function is indicated. Occasional cases of renal failure have been reported; but a cause-and-effect relationship has not always been clearly established.

Salicylates antagonize the uricosuric action of Anturane (sulfinpyrazone) and for this reason their concomitant use is contraindicated in gouty arthritis.

Anturane (sulfinpyrazone) may accentuate the action of coumarin-type anticoagulants and further depress prothrombin activity when these medications are employed simultaneously.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

NOTE: Anturane (sulfinpyrazone) has minimal anti-inflammatory effect and is not intended for the relief of an acute attack of gout.

In the initial stages of therapy, because of the marked ability of Anturane (sulfinpyrazone) to mobilize urates, acute attacks of gouty arthritis may be precipitated.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/8/2004


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Health Resources
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations